Merck And Co
Merck & Co., Inc., commonly referred to as Merck, is a leading global healthcare company headquartered in the United States. Founded in 1891, Merck has established itself as a pioneer in the pharmaceutical industry, focusing on innovative medicines, vaccines, and biologic therapies. With a strong presence in North America, Europe, and Asia, the company is dedicated to improving health outcomes worldwide. Merck's core products include groundbreaking treatments in oncology, infectious diseases, and vaccines, notably the HPV vaccine Gardasil and the cancer immunotherapy Keytruda. These offerings are distinguished by their commitment to research and development, which has led to numerous key milestones in medical advancements. As a market leader, Merck consistently ranks among the top pharmaceutical companies globally, recognised for its contributions to public health and its robust pipeline of future therapies.
DitchCarbon Score
How does Merck And Co's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Merck And Co's score of 75 is higher than 86% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Merck And Co's reported carbon emissions
In 2023, Merck & Co., Inc., headquartered in the US, reported total greenhouse gas emissions of approximately 7,086,700,000 kg CO2e. This includes Scope 1 emissions of about 718,400,000 kg CO2e, Scope 2 emissions of approximately 184,200,000 kg CO2e (market-based), and a significant Scope 3 contribution of around 6,184,100,000 kg CO2e. The company has set ambitious climate commitments, aiming to reduce its operational greenhouse gas emissions (Scopes 1 and 2) by 46% by 2030, using 2019 as a baseline. Additionally, Merck is committed to achieving carbon neutrality across its operations (Scopes 1 and 2) by 2025. Merck's Scope 3 emissions, which encompass indirect emissions from the value chain, are also targeted for a 30% reduction by 2030. The company has aligned its targets with the Science Based Targets initiative (SBTi), committing to a net-zero target for all greenhouse gas emissions by 2045. This comprehensive approach reflects Merck's dedication to sustainability and its proactive stance in addressing climate change within the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 417,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 367,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 64,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Merck And Co is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
